Literature DB >> 16368991

Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice.

Mason X Zhang1, M Charlotte Bohlman, Carol Itatani, Dennis R Burton, Paul W H I Parren, Stephen C St Jeor, Thomas R Kozel.   

Abstract

Mannan is a major cell wall component found in Candida species. Natural antimannan antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length immunoglobulin G1 antibody, M1g1, and M1g1 was produced in CHO cells. The M1g1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23 degrees C and 37 degrees C and uniform over the cell surface. BALB/c mice passively immunized with M1g1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1g1 dose-dependent manner (P, 0.08 to <0.001) and by reduction in number of infection foci and their size in the kidney. In vitro studies found that M1g1 promoted phagocytosis and phagocytic killing of C. albicans yeast cells by mouse peritoneal macrophages and was required for activation of the mouse complement cascade. Thus, human antimannan antibody may have a protective role in host resistance to systemic candidiasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368991      PMCID: PMC1346657          DOI: 10.1128/IAI.74.1.362-369.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Beta-1,2-mannosylation of Candida albicans mannoproteins and glycolipids differs with growth temperature and serotype.

Authors:  P A Trinel; T Jouault; J E Cutler; D Poulain
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

2.  Enhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragment.

Authors:  Melanie Wellington; Joseph M Bliss; Constantine G Haidaris
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

3.  Recombinant human antibody single chain variable fragments reactive with Candida albicans surface antigens.

Authors:  C G Haidaris; J Malone; L A Sherrill; J M Bliss; A A Gaspari; R A Insel; M A Sullivan
Journal:  J Immunol Methods       Date:  2001-11-01       Impact factor: 2.303

4.  Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody.

Authors:  Y Han; M H Riesselman; J E Cutler
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

5.  Biological activities of naturally occurring antibodies reactive with Candida albicans mannan.

Authors:  Thomas R Kozel; Randall S MacGill; Ann Percival; Qing Zhou
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2.

Authors:  Manuel Vilanova; Luzia Teixeira; Iris Caramalho; Egídio Torrado; Andreia Marques; Pedro Madureira; Adília Ribeiro; Paula Ferreira; Miguel Gama; Jocelyne Demengeot
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

7.  Beta-1,2- and alpha-1,2-linked oligomannosides mediate adherence of Candida albicans blastospores to human enterocytes in vitro.

Authors:  Fredéric Dalle; Thierry Jouault; Pierre André Trinel; Jacques Esnault; Jean Maurice Mallet; Philippe d'Athis; Daniel Poulain; Alain Bonnin
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

8.  Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Authors:  Ruth C Matthews; Gordon Rigg; Samantha Hodgetts; Tracey Carter; Caroline Chapman; Carl Gregory; Chris Illidge; James Burnie
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis.

Authors:  Angel Viudes; Anna Lazzell; Sofia Perea; William R Kirkpatrick; Javier Peman; Thomas F Patterson; Jose P Martinez; José L López-Ribot
Journal:  FEMS Microbiol Lett       Date:  2004-03-19       Impact factor: 2.742

10.  A novel glyco-conjugate vaccine against fungal pathogens.

Authors:  Antonella Torosantucci; Carla Bromuro; Paola Chiani; Flavia De Bernardis; Francesco Berti; Chiara Galli; Francesco Norelli; Cinzia Bellucci; Luciano Polonelli; Paolo Costantino; Rino Rappuoli; Antonio Cassone
Journal:  J Exp Med       Date:  2005-09-05       Impact factor: 14.307

View more
  14 in total

1.  Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Posaconazole prophylaxis in experimental systemic zygomycosis.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Alfredo Santinelli; Annette W Fothergill; Eleonora Pisa; Daniele Giannini; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

Review 3.  The protective role of immunoglobulins in fungal infections and inflammation.

Authors:  Sri Ramulu Elluru; Srini V Kaveri; Jagadeesh Bayry
Journal:  Semin Immunopathol       Date:  2014-11-18       Impact factor: 9.623

Review 4.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

5.  Influence of mannan and glucan on complement activation and C3 binding by Candida albicans.

Authors:  Gayle M Boxx; Thomas R Kozel; Casey T Nishiya; Mason X Zhang
Journal:  Infect Immun       Date:  2009-12-22       Impact factor: 3.441

6.  Select Streptococci Can Degrade Candida Mannan To Facilitate Growth.

Authors:  Robert Fultz; Taylor Ticer; Janiece Glover; Leah Stripe; Melinda A Engevik
Journal:  Appl Environ Microbiol       Date:  2021-12-22       Impact factor: 5.005

7.  Influence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice.

Authors:  Casey T Nishiya; Gayle M Boxx; Kerry Robison; Carol Itatani; Thomas R Kozel; Mason X Zhang
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

8.  Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.

Authors:  Gayle M Boxx; Casey T Nishiya; Thomas R Kozel; Mason X Zhang
Journal:  Mol Immunol       Date:  2008-11-26       Impact factor: 4.407

9.  Scaling-up and production of therapeutic antibodies for preclinical studies.

Authors:  Yang Feng; Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2009

10.  In situ IgM production and clonal expansion of B-1 cells in peritoneal cavity promote elimination of C. albicans infection in IgH transgenic mice with VH derived from a natural antibody.

Authors:  Rong Tian; Meng Fu; Zhuo Zhang; Jing Ren; Jingang An; Yufeng Liu; Wei Li
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.